The association between maternal urinary phthalate concentrations and blood pressure in pregnancy: The HOME Study

Erika F Werner, Joseph M Braun, Kimberly Yolton, Jane C Khoury, Bruce P Lanphear, Erika F Werner, Joseph M Braun, Kimberly Yolton, Jane C Khoury, Bruce P Lanphear

Abstract

Background: Exposure to phthalates, a class of endocrine disrupting chemicals, is ubiquitous. We examined the association of urinary phthalate metabolite concentrations during pregnancy with maternal blood pressure and risk of pregnancy-induced hypertensive diseases.

Methods: We used data from the Health Outcomes and Measures of the Environment Study, a prospective birth cohort of low-risk pregnant women recruited between March 2003 and January 2006. We analyzed maternal urine samples collected at 16 and 26 weeks gestation for 9 phthalate monoester metabolites reflecting exposure to 6 phthalate diesters. Outcomes included maternal blood pressure at <20 and ≥ 20 weeks gestation and pregnancy induced hypertensive diseases (gestational hypertension, preeclampsia, eclampsia, and HELLP syndrome).

Results: Data were available for 369 women who gave birth to singleton, live-born infants without congenital anomalies. Of the phthalate metabolites evaluated, only mono-benzyl phthalate (MBzP) concentrations were significantly associated with maternal diastolic blood pressure at <20 weeks gestation. Women in the third MBzP tercile at 16 weeks gestation had diastolic blood pressure 2.2 (95% CI: 0.5-3.9) mm Hg higher at <20 weeks gestation and 2.8 (95% CI: 0.9-4.7) mm Hg higher at ≥ 20 weeks gestation compared to women in the first tercile. Compared to women in the first tercile, women in the top MBzP tercile at 16 weeks had an increased risk of developing pregnancy-induced hypertensive diseases (RR = 2.92, 95 % CI 1.15-7.41, p-value for trend = 0.01). MBzP concentrations at 26 weeks gestation were not as strongly associated with blood pressure at ≥ 20 weeks gestation or risk of pregnancy-induced hypertensive diseases.

Conclusion: This study suggests that maternal urinary MBzP concentrations may be associated with increased diastolic blood pressure and risk of pregnancy-induced hypertensive diseases.

Figures

Fig. 1
Fig. 1
Adjusted diastolic blood pressure at n = 369, 719 repeated measurements). *- Adjusted for maternal race, age at delivery, household income, education, marital status, serum cotinine concentrations, parity, BMI at 16 weeks gestation, previous use of medication for high blood pressure, and week of pregnancy that the blood pressure measurement was taken
Fig. 2
Fig. 2
Highest diastolic blood pressure >20 weeks gestation according to urinary MBzP tercile at 16 weeks of pregnancy (n = 371, 736 repeated measurements). *- Adjusted for maternal race, age at delivery, household income, education, marital status, serum cotinine concentrations, parity, BMI at 16 weeks gestation, previous use of medication for high blood pressure, and week of pregnancy that the blood pressure measurement was taken

References

    1. Trasande L, Sathyanarayana S, Spanier A, Trachtman H, Attina TM, Urbina EM. Urinary Phthalates Are Associated with Higher Blood Pressure in Childhood. J Pediatr. 2013;163(3):747–753. doi: 10.1016/j.jpeds.2013.03.072.
    1. Wiberg B, Lind PM, Lind L. Serum levels of monobenzylphthalate (MBzP) is related to carotid atherosclerosis in the elderly. Environ Res. 2014;133:348–52. doi: 10.1016/j.envres.2014.06.009.
    1. Ferguson KK, Cantonwine DE, Rivera-Gonzalez LO, Loch-Caruso R, Mukherjee B, Anzalota Del Toro LV, et al. Urinary phthalate metabolite associations with biomarkers of inflammation and oxidative stress across pregnancy in Puerto Rico. Environ Sci Technol. 2014;48(12):7018–25. doi: 10.1021/es502076j.
    1. Woodruff TJ, Zota AR, Schwartz JM. Environmental chemicals in pregnant women in the United States: NHANES 2003–2004. Environ Health Perspect. 2011;119(6):878–85. doi: 10.1289/ehp.1002727.
    1. Sathyanarayana S. Phthalate and children's health. Curr Probl Pediatr Adolesc Health Care. 2008;38(2):34–49. doi: 10.1016/j.cppeds.2007.11.001.
    1. Boas M, Feldt-Rasmussen U, Main KM. Thyroid effects of endocrine disrupting chemicals. Mol Cell Endocrinol. 2012;355(2):240–8. doi: 10.1016/j.mce.2011.09.005.
    1. Howdeshell KL, Furr J, Lambright CR, Wilson VS, Ryan BC, Gray LE., Jr Gestational and lactational exposure to ethinyl estradiol, but not bisphenol A, decreases androgen-dependent reproductive organ weights and epididymal sperm abundance in the male long evans hooded rat. Toxicol Sci. 2008;102(2):371–82. doi: 10.1093/toxsci/kfm306.
    1. Ye L, Guo J, Ge RS. Environmental pollutants and hydroxysteroid dehydrogenases. Vitam Horm. 2014;94:349–90. doi: 10.1016/B978-0-12-800095-3.00013-4.
    1. Ferguson KK, Loch-Caruso R, Meeker JD. Urinary phthalate metabolites in relation to biomarkers of inflammation and oxidative stress: NHANES 1999–2006. Environ Res. 2011;111(5):718–26. doi: 10.1016/j.envres.2011.02.002.
    1. Braun JM, Smith KW, Williams PL, Calafat AM, Berry K, Ehrlich S, et al. Variability of urinary phthalate metabolite and bisphenol A concentrations before and during pregnancy. Environ Health Perspect. 2012;120(5):739–45. doi: 10.1289/ehp.1104139.
    1. Myatt L, Clifton RG, Roberts JM, Spong CY, Wapner RJ, Thorp JM, Jr, et al. Can changes in angiogenic biomarkers between the first and second trimesters of pregnancy predict development of pre-eclampsia in a low-risk nulliparous patient population? BJOG. 2013;120(10):1183–91. doi: 10.1111/1471-0528.12128.
    1. Moutguin JM, Rainville C, Giroux L, Raynauld P, Amyot G, Bilodeau R, Pelland N. A prospective study of blood pressure in pregnancy: prediction of preeclampsia. Am J Obstet Gynecol. 1985;151(2):191–6. doi: 10.1016/0002-9378(85)90010-9.
    1. Silva MJ, Barr DB, Reidy JA, Malek NA, Hodge CC, Caudill SP, et al. Urinary levels of seven phthalate metabolites in the U.S. population from the National Health and Nutrition Examination Survey (NHANES) 1999–2000. Environ Health Perspect. 2004;112(3):331–8. doi: 10.1289/ehp.6723.
    1. Ferguson KK, McElrath TF, Ko YA, Mukherjee B, Meeker JD. Variability in urinary phthalate metabolite levels across pregnancy and sensitive windows of exposure for the risk of preterm birth. Environ Int. 2014;70:118–24. doi: 10.1016/j.envint.2014.05.016.
    1. Calafat AM, Longnecker MP, Koch HM, Swan SH, Hauser R, Goldman LR, et al. Optimal Exposure Biomarkers for Nonpersistent Chemicals in Environmental Epidemiology. Environ Health Perspect. 2015;123(7):A166–8. doi: 10.1289/ehp.1510041.
    1. Redman CW, Sargent IL, Staff AC. Making sense of pre-eclampsia e Two placental causes of preeclampsia? Placenta. 2014;28:S20–25. doi: 10.1016/j.placenta.2013.12.008.
    1. Zota AR, Calafat AM, Woodruff TJ. Temporal Trends in Phthalate Exposures: Findings from the National Health and Nutrition Examination Survey, 2001–2010. Environ Health Perspect. 2014;122(3):235–41.
    1. Calafat AM, Needham LL. What additional factors beyond state-of-the-art analytical methods are needed for optimal generation and interpretation of biomonitoring data? Environ Health Perspect. 2009;117:1481–5. doi: 10.1289/ehp.0901108.

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit